Related references
Note: Only part of the references are listed.Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Epigenetic therapy for ovarian cancer: promise and progress
Sara Moufarrij et al.
CLINICAL EPIGENETICS (2019)
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Yang Liu et al.
CANCER CELL (2018)
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma
Sarah S. Bernards et al.
GYNECOLOGIC ONCOLOGY (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
Zsofia Sztupinszki et al.
NPJ BREAST CANCER (2018)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2017)
missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform
Belinda Phipson et al.
BIOINFORMATICS (2016)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang et al.
CANCER RESEARCH (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Homologous recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer
G.B. Mills et al.
GYNECOLOGIC ONCOLOGY (2016)
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
Mariam M. AlHilli et al.
GYNECOLOGIC ONCOLOGY (2016)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
NOD-scidIl2rg tm1Wjl and NOD-Rag1 null Il2rg tm1Wjl : A Model for Stromal Cell-Tumor Cell Interaction for Human Colon Cancer
Justin Maykel et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
I. Ruscito et al.
EUROPEAN JOURNAL OF CANCER (2014)
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
Monique D. Topp et al.
MOLECULAR ONCOLOGY (2014)
Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status
J. M. Cunningham et al.
SCIENTIFIC REPORTS (2014)
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
Joshy George et al.
CLINICAL CANCER RESEARCH (2013)
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
Olafur A. Stefansson et al.
EPIGENETICS (2012)
Germline RAD51C mutations confer susceptibility to ovarian cancer
Chey Loveday et al.
NATURE GENETICS (2012)
RAD51C is a susceptibility gene for ovarian cancer
Liisa M. Pelttari et al.
HUMAN MOLECULAR GENETICS (2011)
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Yvette Drew et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Phase 1 and Pharmacodynamic Study of Decitabine in Combination With Carboplatin in Patients With Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer
Fang Fang et al.
CANCER (2010)
BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors
Jurgen Veeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
Alfons Meindl et al.
NATURE GENETICS (2010)
The implications of heterogeneous DNA methylation for the accurate quantification of methylation
Thomas Mikeska et al.
EPIGENOMICS (2010)
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas
Elizabeth M. Swisher et al.
MOLECULAR CANCER (2009)
Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene
Ida LM Candiloro et al.
Epigenetics & Chromatin (2008)
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype
Cameron Snell et al.
BREAST CANCER RESEARCH (2008)
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
Jing Wang Chiang et al.
GYNECOLOGIC ONCOLOGY (2006)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
